Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening

About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be achieved by lowering the fecal immunochemical test positivity threshold, without additional mt-sRNA testing. The findings are similar to previous observations for multitarget stool DNA testing.

Corresponding Author: To contact the corresponding author, Hermann Brenner, M.D., M.P.H., email h.brenner@dkfz.de.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jama.2024.9289)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Media advisory: This study is being released to coincide with the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time